Pfizer-backed UK biotech raises £25M to advance mitophagy pipeline
Mission announces publication outlining potential of experimental drug MTX325
CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the successful completion of its first Phase I clinical assessment for lead USP30 DUB inhibitor, MTX652.
Safety, tolerability and pharmacokinetic endpoints for MTX652 have been successfully met
CAMBRIDGE, England--(BUSINESS WIRE)--Mission Therapeutics (“Mission”), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), announces that CEO, Dr Anker Lundemose, will present at the upcoming J.P Morgan Healthcare Conference.
Mission Therapeutics has been granted approval to take its lead USP30 deubiquitinating enzyme (DUB) inhibitor – MTX652 – into a clinical study.